Loading
NASDAQHealthcareBiotechnology
Latest quote
$3.735
−$0.015 · -0.40%
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
Regular session
$3.735
−$0.015 · -0.40%
Regular session · ET · Market data may be delayed.
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
Day range
Current $3.735
52-week range
Current $3.735
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
34
Expensive
Sentiment
35
Bearish
Risk
86
Extreme Risk
Momentum
19
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
Day range
Current $3.735
52-week range
Current $3.735
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 80M USD | 2.81M USD | 6.34M USD | 19.16M USD |
| Cost of goods sold | 1.39M USD | 63.39M USD | 71.8M USD | 76.78M USD | 69.7M USD |
| Gross profit | −1.39M USD | 16.61M USD | −69M USD | −70.44M USD | −50.54M USD |
| Research and development | 56.1M USD | 63.39M USD | 71.8M USD | 76.78M USD | 69.7M USD |
| Selling, general, and administrative | 28.67M USD | 36.45M USD | 41.67M USD | 41.69M USD | 30.52M USD |
| Operating expenses | 83.38M USD | 38.51M USD | 41.67M USD | 42.12M USD | 30.52M USD |
| Interest income | — | — | — | — | 207K USD |
| Depreciation and amortization | 1.39M USD | 1.59M USD | 2.17M USD | 2.41M USD | 2.52M USD |
| Operating income | −84.77M USD | −21.9M USD | −110.66M USD | −112.56M USD | −81.05M USD |
| Net income | −74.88M USD | −9.73M USD | −97.34M USD | −109.87M USD | −80.85M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$3.60
3.61% downsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI8.07M0.00%2.3T USD0.03%$381.42+0.49%
iShares Russell 2000 ETFIWM6.67M0.01%77.7B USD0.19%$278.77+0.43%
iShares Russell 2000 Value ETFIWN2.34M0.02%13.75B USD0.24%$211.13+0.09%
Vanguard Extended Market ETFVXF2.15M0.00%95.4B USD0.05%$234.59+0.63%
iShares Biotechnology ETFIBB2.15M0.02%10.41B USD0.44%$203.85+1.68%
Fidelity Enhanced Small Cap ETFFESM1.87M0.03%6.41B USD0.28%$45.43+0.40%
Vanguard Russell 2000 ETFVTWO1.32M0.01%18B USD0.06%$112.59+0.44%
Schwab U.S. Small-Cap ETFSCHA1.2M0.01%21.73B USD0.03%$32.795+0.41%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMiShares Russell 2000 Value ETFIWNVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBFidelity Enhanced Small Cap ETFFESMVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
